Patents by Inventor Fu-An Kang

Fu-An Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR DELIVERY OF POLYNUCLEOTIDES
    Publication number: 20250127912
    Abstract: The present disclosure provides compositions for delivering polynucleotides and methods of use thereof for treating genetic diseases. The present disclosure also provides polynucleotide conjugates. The present disclosure further provides anti-transferrin receptor antibodies.
    Type: Application
    Filed: June 21, 2024
    Publication date: April 24, 2025
    Inventors: Anthony Saleh, Charles Marusak, Tishan Williams, Fu-An Kang
  • Synthetic processes and synthetic intermediates
    Patent number: 12173013
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Grant
    Filed: January 31, 2023
    Date of Patent: December 24, 2024
    Assignee: Taxis Pharmaceuticals, Inc.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit K. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES
    Publication number: 20230257397
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Application
    Filed: January 31, 2023
    Publication date: August 17, 2023
    Applicant: TAXIS PHARMACEUTICALS, INC.
    Inventors: Sanjeevani GHONE, Fu-An KANG, Nareshkumar JAIN, Ajit K. PARHI, Ravi PONNAIAH, Anil Kumar SONI, Siva Rami Reddy ATHUNURI, Thrisulapani KORRAKUTI, Pullarao SEELAM
  • Thiazolidinone and oxazolidinone compounds and formulations
    Patent number: 11014940
    Abstract: Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: John Fitzgerald Traverse, Sanjeevani Ghone, Fu-An Kang, Francisco Velazquez
  • SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES
    Publication number: 20210139508
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Application
    Filed: August 19, 2020
    Publication date: May 13, 2021
    Applicant: TAXIS PHARMACEUTICALS, INC.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit K. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • Synthetic processes and synthetic intermediates
    Patent number: 10774093
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 15, 2020
    Assignee: Taxis Pharmaceuticals, Inc.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit S. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATES
    Publication number: 20200055870
    Abstract: The invention provides synthetic intermediates and synthetic processes that are useful for preparing the antibacterial agent TXA709:
    Type: Application
    Filed: March 30, 2018
    Publication date: February 20, 2020
    Applicant: TAXIS PHARMACEUTICALS, INC.
    Inventors: Sanjeevani Ghone, Fu-An Kang, Nareshkumar Jain, Ajit S. Parhi, Ravi Ponnaiah, Anil Kumar Soni, Siva Rami Reddy Athunuri, Thrisulapani Korrakuti, Pullarao Seelam
  • Octahydro-cyclopentapyrrolyl antagonists of CCR2
    Patent number: 9024017
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: May 5, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Chaozhong Cai, David F. McComsey, Zhihua Sui, Fu-An Kang
  • Fused cyclopentyl antagonists of CCR2
    Patent number: 8822460
    Abstract: The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Grant
    Filed: April 4, 2013
    Date of Patent: September 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael P. Winters, Nagy E. Fawzy, Fu-An Kang, Zhihua Sui
  • OCTAHYDRO-CYCLOPENTAPYRROLYL ANTAGONISTS OF CCR2
    Publication number: 20140024646
    Abstract: The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, Z1 and Z2 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    Type: Application
    Filed: July 16, 2013
    Publication date: January 23, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Chaozhong Cai, David F. MCCOMSEY, Zhihua Sui, Fu-An Kang
  • Oxa-steroids derivatives as selective progesterone receptor modulators
    Patent number: 7763648
    Abstract: The present invention is directed to 7 oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
    Type: Grant
    Filed: February 16, 2007
    Date of Patent: July 27, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Fu-An Kang, Nareshkumar F. Jain, Zhihua Sui
  • OXA-STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS
    Publication number: 20070197635
    Abstract: The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
    Type: Application
    Filed: February 16, 2007
    Publication date: August 23, 2007
    Inventors: Fu-An Kang, Nareshkumar F. Jain, Zhihua Sui
  • Triazine compounds as inhibitors of bacterial type III protein secretion systems
    Publication number: 20050250945
    Abstract: In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections, are provided. In another aspect of the invention, methods are provided for the inhibition of Type III protein secretion and/or the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections using the compounds of the invention.
    Type: Application
    Filed: May 6, 2005
    Publication date: November 10, 2005
    Inventors: Xiaobing Li, Fu-An Kang, Mark Macielag